Compare United States Copper Index Fund (CPER) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Pfizer Inc — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $716.81M), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 222.6× United States Copper Index Fund's market cap, and Pfizer Inc pays a 6.14% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Pfizer Inc for 158 Days on average.
| CPER | PFE | |
|---|---|---|
Market Cap | $716.81M | $159.59B |
Volume | 388,730 | 30,937,010 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $29.02 |
52-Week Low | $30.27 | $23.67 |
Typical Hold Time | 48 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
